Evidence map›Paper›PMID 42774546›Full record

ArticleKidney international reports2026

Design and Baseline Characteristics of CONCORD, a Trial of Novel Therapies for Depression in CKD.

Meredith C McAdams, L Parker Gregg, Thomas Carmody, Joseph M Trombello, Lynnel C Goodman, Amelia Dubovsky, Rula Abdulrahman, Bethany Roehm, Shani Shastri, Katherine R Tuttle and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meredith C McAdamsDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
L Parker GreggSection of Nephrology, Department of Medicine, Baylor College of Medicine, Selzman Institute for Kidney Health, Houston, Texas, USA.
Thomas CarmodyDepartment of Health Data Science and Biostatistics, Peter O'Donnell Jr School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Joseph M TrombelloDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Lynnel C GoodmanDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Amelia DubovskyDepartment of Psychiatry, University of Washington, Seattle, Washington, USA.
Rula AbdulrahmanDivision of Nephrology, Department of Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA.
Bethany RoehmDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Shani ShastriDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Katherine R TuttleDivision of Nephrology, Department of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
Madhukar H TrivediDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Rajnish MehrotraDivision of Nephrology, Department of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
S Susan HedayatiDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Funding

Mechanisms for Behavior Change and Maintenance of Treatment for CKD Comorbid DepressionR01DK124379 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HEDAYATI, SUSAN · 2020 to 2024
$3.8M
CSRD VA IK2 CX002368NIDDK NIH HHS R01 DK124379
6 · The paper itself

Abstract

Background: Major depressive disorder (MDD) is prevalent in patients with chronic kidney disease (CKD) and is associated with adverse outcomes. Traditional pharmacologic and nonpharmacologic treatments as monotherapy have shown limited efficacy for MDD, necessitating studies of other treatment options. Methods: The Combination of Novel Therapies for CKD Comorbid Depression Trial (CONCORD) is a multicenter, randomized, placebo-controlled trial to evaluate 2 distinct treatment strategies compared with control in participants with CKD G3b-5 and MDD, beginning with 8 weeks of monotherapy with single-blind behavioral activation teletherapy (BAT) plus double-blind placebo, or double-blind bupropion-sustained release once daily plus single-blind attention control clinical management (CM). The assigned monotherapy is continued for another 8 weeks if depression remits. If depression fails to remit, the participant will receive combination therapy with bupropion and BAT for 8 weeks. The control arm includes parallel frequency-matched single-blind CM plus double-blind placebo for 16 weeks. The primary outcome is improvement in depression severity from baseline to 16 weeks. Secondary outcomes include safety and tolerability. Association with inflammation and effects on patient-reported outcomes (PROs) will also be explored. Results: A total of 202 patients were randomized across 3 US sites. Mean (SD) age was 56 (12) years and mean estimated glomerular filtration rate 24.6 (10.9) ml/min per 1.73 m Conclusions: CONCORD will provide evidence for the effectiveness of bupropion, BAT, and combination therapy for depression in adults with CKD, which can inform changes in clinical practice.

Indexed as

Bupropionchronic kidney diseasedepressionrandomized controlled trialteletherapytreatment

Identifiers

PMID42774546
PMCPMC13594935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.